Announcements Trials
Browse Landscape

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 20Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Flow Cytometry 36Gene Expression Profiling 34Surveys and Questionnaires 27Polymerase Chain Reaction 24Microarray Analysis 23Blood Specimen Collection 19Interviews as Topic 18Imatinib Mesylate 15Amplified Fragment Length Polymorphism Analysis 14Reverse Transcriptase Polymerase Chain Reaction 13Cytogenetic Analysis 13Rituximab 12venetoclax 11nilotinib 10Psychiatric Rehabilitation 10Dasatinib 10Immunologic Techniques 9DNA Methylation 9Blotting, Western 9ponatinib 8Watchful Waiting 8Observation 8In Situ Hybridization, Fluorescence 8Base Sequence 8Azacitidine 8ibrutinib 7fludarabine 7bosutinib 7Therapeutics 7Specimen Handling 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × duvelisib × Other hematologic neoplasm × Clear all
NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Ruijin Hospital

Not yet recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

NCT04342117 2021-03-17

REAL

SecuraBio

Terminated
2 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡